The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

As the use of GLP-1 medications such as Ozempic, Wegovy and Mounjaro becomes more widespread for weight loss, a growing concern is the unintended loss of muscle mass that often accompanies rapid fat ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Weight-loss supplements recommended by influencers on social mead are generally ineffective for weight loss, but do have some benefits.

Retirees looking for dividend growth stocks at a reasonable price have ample reasons to look outside of America, especially ...

An expert has revealed the potential harm you could cause to your body if you pause taking Ozempic, then resume again.